PT3052139T - Pré-saturação do fígado e administração subsequente do agente de contraste - Google Patents
Pré-saturação do fígado e administração subsequente do agente de contrasteInfo
- Publication number
- PT3052139T PT3052139T PT14780805T PT14780805T PT3052139T PT 3052139 T PT3052139 T PT 3052139T PT 14780805 T PT14780805 T PT 14780805T PT 14780805 T PT14780805 T PT 14780805T PT 3052139 T PT3052139 T PT 3052139T
- Authority
- PT
- Portugal
- Prior art keywords
- liver
- saturation
- contrast agent
- subsequent administration
- administration
- Prior art date
Links
- 239000002872 contrast media Substances 0.000 title 1
- 210000004185 liver Anatomy 0.000 title 1
- 238000000079 presaturation Methods 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/04—X-ray contrast preparations
- A61K49/0433—X-ray contrast preparations containing an organic halogenated X-ray contrast-enhancing agent
- A61K49/0447—Physical forms of mixtures of two different X-ray contrast-enhancing agents, containing at least one X-ray contrast-enhancing agent which is a halogenated organic compound
- A61K49/0461—Dispersions, colloids, emulsions or suspensions
- A61K49/0471—Perflubron, i.e. perfluoroctylbromide, C8F17Br emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
- A61K49/1806—Suspensions, emulsions, colloids, dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0063—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres
- A61K49/0069—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form
- A61K49/0076—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form dispersion, suspension, e.g. particles in a liquid, colloid, emulsion
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Dispersion Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Radiology & Medical Imaging (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13186703 | 2013-09-30 | ||
| EP14169433 | 2014-05-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT3052139T true PT3052139T (pt) | 2019-02-08 |
Family
ID=51660460
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT14780805T PT3052139T (pt) | 2013-09-30 | 2014-09-25 | Pré-saturação do fígado e administração subsequente do agente de contraste |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US10786583B2 (pt) |
| EP (1) | EP3052139B1 (pt) |
| JP (1) | JP6587622B2 (pt) |
| CN (1) | CN105592862B (pt) |
| DK (1) | DK3052139T3 (pt) |
| ES (1) | ES2709887T3 (pt) |
| HU (1) | HUE042167T2 (pt) |
| PL (1) | PL3052139T3 (pt) |
| PT (1) | PT3052139T (pt) |
| TW (1) | TWI679990B (pt) |
| WO (1) | WO2015044312A1 (pt) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3203256A1 (en) * | 2016-02-02 | 2017-08-09 | B. Braun Melsungen AG | Calibration of mri systems using pre-defined concentrations of 19f isotopes as reference |
| KR20180054351A (ko) | 2016-11-15 | 2018-05-24 | 삼성전자주식회사 | 생체 성분 측정 장치 및 방법 |
| AU2018314406A1 (en) | 2017-08-07 | 2020-02-20 | Université De Genève | Nanoemulsion of iodinated fatty acids for CT imaging |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4405627A1 (de) * | 1994-02-22 | 1995-08-24 | Hoechst Ag | Fluorkohlenwasserstoffe enthaltende Ölemulsionen |
| US5861175A (en) * | 1996-03-15 | 1999-01-19 | Alliance Pharmaceutical Corp. | Use of fluorocarbons for diagnosis and treatment of articular disorders |
| JP2007523090A (ja) * | 2004-02-10 | 2007-08-16 | バーンズ−ジューイッシュ ホスピタル | デコイ系を用いたターゲティングされた微粒子剤の有効性および安全性の改善方法 |
| CN101045042B (zh) * | 2006-03-30 | 2010-09-22 | 上海医药工业研究院 | 丙泊酚注射液及制备方法 |
| US9000048B2 (en) * | 2006-11-28 | 2015-04-07 | Wisconsin Alumni Research Foundation | Fluoropolymer-based emulsions for the intravenous delivery of fluorinated volatile anesthetics |
| DE102007015598A1 (de) * | 2007-03-29 | 2008-10-02 | Heinrich-Heine-Universität Düsseldorf | Verwendung von fluorhaltigen Verbindungen zu Diagnosezwecken mit Hilfe bildgebender Verfahren |
| US20080319315A1 (en) * | 2007-06-07 | 2008-12-25 | Beth Israel Deaconess Medical Center | Method of reducing interferences in positron emission tomography |
| CN101879138A (zh) * | 2009-05-06 | 2010-11-10 | 上海恒瑞医药有限公司 | 长春花生物碱纳米乳剂注射液及其制备方法 |
-
2014
- 2014-09-25 DK DK14780805.9T patent/DK3052139T3/en active
- 2014-09-25 US US15/023,722 patent/US10786583B2/en active Active
- 2014-09-25 ES ES14780805T patent/ES2709887T3/es active Active
- 2014-09-25 CN CN201480053851.0A patent/CN105592862B/zh active Active
- 2014-09-25 PT PT14780805T patent/PT3052139T/pt unknown
- 2014-09-25 HU HUE14780805A patent/HUE042167T2/hu unknown
- 2014-09-25 PL PL14780805T patent/PL3052139T3/pl unknown
- 2014-09-25 JP JP2016544760A patent/JP6587622B2/ja active Active
- 2014-09-25 EP EP14780805.9A patent/EP3052139B1/en active Active
- 2014-09-25 WO PCT/EP2014/070569 patent/WO2015044312A1/en active Application Filing
- 2014-09-29 TW TW103133746A patent/TWI679990B/zh active
Also Published As
| Publication number | Publication date |
|---|---|
| EP3052139A1 (en) | 2016-08-10 |
| TW201545766A (zh) | 2015-12-16 |
| PL3052139T3 (pl) | 2019-05-31 |
| CN105592862A (zh) | 2016-05-18 |
| TWI679990B (zh) | 2019-12-21 |
| ES2709887T3 (es) | 2019-04-22 |
| JP2016531939A (ja) | 2016-10-13 |
| HUE042167T2 (hu) | 2019-06-28 |
| EP3052139B1 (en) | 2018-11-07 |
| WO2015044312A1 (en) | 2015-04-02 |
| JP6587622B2 (ja) | 2019-10-09 |
| US20160228582A1 (en) | 2016-08-11 |
| DK3052139T3 (en) | 2019-02-18 |
| CN105592862B (zh) | 2020-09-29 |
| US10786583B2 (en) | 2020-09-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1226301A1 (zh) | 修飾的治療劑及其組合物 | |
| HRP20180635T1 (hr) | Pirazolamidni spoj i njegova upotreba u medicini | |
| IL265876A (en) | Preparations that include 15-ohepa and methods of using them | |
| HK1223975A1 (zh) | 含納米氣泡的組合物及其用途 | |
| EP2961382A4 (en) | TOPICAL COMPOSITIONS AND METHODS OF USE | |
| HK1198452A1 (en) | Framework of dust-prevention film assembly and dust-prevention film assembly using the framework | |
| IL246280B (en) | Therapeutic methods and preparations | |
| ZA201509262B (en) | Tuberculosis compositions and methods of using the same | |
| IL240248A0 (en) | Met-binding substances and their uses | |
| EP3056215A4 (en) | Combination of anti-fgfr2 antibody and other agent | |
| EP2976091C0 (de) | Antioxidativ wirksame zusammensetzung und deren verwendung | |
| EP3062740A4 (en) | Positioning agent and method of using the same | |
| HK1219691A1 (zh) | 醫藥組成物及其用途 | |
| EP2983789A4 (en) | COMPOSITIONS AND METHODS OF DELIVERING THERAPY AGENTS | |
| EP3057596A4 (en) | Compositions and methods of administering same | |
| HUE042167T2 (hu) | Máj elõzetes telítése és kontraszt anyag ezt követõ adagolása | |
| GB201307082D0 (en) | Pharmaceutical composition comprising 15-HETrE and methods of using the same | |
| SG10201701154RA (en) | Anti-viral methods and the use of an anti-viral agent | |
| GB201322869D0 (en) | Therapeutic agents and delivery with microspheres | |
| GB201300628D0 (en) | Compositions comprising 15-OHEPA and methods of using the same | |
| AU2013903955A0 (en) | Compositions and Methods of Administering Same | |
| GB201319255D0 (en) | Therapeutic compositions and methods |